CDK4 and dedifferentiated liposarcoma: The CDK4-targeting agent palbociclib is well tolerated but achieves only limited activity as a single agent, with only 1 patient out of 60 exhibiting an objective response in a recent phase 2 study of patients with advanced DDLPS [6].